The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life

Descriptive pharmacoepidemiological study of patients treated with Iressa

Inclusion Criteria:

• Patients treated with Iressa

Exclusion Criteria:

• Patient included in a therapeutic trial comprising protocol use of Iressa
• Patient included in a therapeutic trial (Huriet-Serusclat Act)
• Patient refusing to participate in the study

Hospital, clinic